The global Joint Pain Injections market size was estimated at USD 4.15 billion in 2021 and is expected to surpass around USD 9.10 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 7.9% during the forecast period 2022 to 2030.
Joint Pain Injections Market Introduction
Injections for joint pain are usually administered directly into the joint to relieve pain and minimize swelling and discomfort. Joint discomfort is particularly common in the elderly population as a result of pre-existing illnesses or diseases. Musculoskeletal conditions such as arthritis and sacroiliac joint pain that cause pain and inflammation could contribute to joint discomfort. Rise in prevalence of osteoarthritis and rheumatoid arthritis; and increase in need for affordable treatments for such conditions are expected to increase the scope for joint pain injections market during the forecast period.
Report Scope of the Joint Pain Injections Market
Report Coverage |
Details |
Market Size |
USD 9.10 Billion by 2030 |
Growth Rate |
CAGR of 7.9% from 2022 to 2030 |
Largest Market |
North America |
Fastest Growing Market |
Asia Pacific |
Base Year |
2021 |
Forecast Period |
2022 to 2030 |
Segments Covered |
Joint Type, Injection Type, Distribution Channel and Region, |
Companies Mentioned |
|
High Unmet Needs of Patients with Joint Pain to Drive Global Joint Pain Injections Market
Joint pain due to arthritis is a prevalent complaint among people. It is also a significant contributor to reduced mobility and impairment. Currently, the available therapy options are insufficient, as they primarily concentrate on symptom alleviation and pain management. There are no medicines that can reverse or stop the progression of arthritis. Demand for new treatment options for joint pain is high, as people do not get relief from the already available medications. This is expected to drive the global joint pain injections market.
Rise in Prevalence of Arthritis and Other Bone-related Disorders to Propel Global Joint Pain Injections Market
Arthritis is the most common cause of adult impairment globally. According to the Arthritis Foundation, osteoarthritis is the biggest cause of chronic impairment among the world's population. It ranks sixth among all forms of disability globally. Moreover, it is one of the most widespread musculoskeletal disorders, affecting 10% of the world's population aged over 60. In high-income countries, osteoarthritis affects up to 80% of those over 65, as it becomes more common with age. As the world's population ages, degenerative joint disease illnesses such as osteoarthritis are likely to affect at least 130 million people by 2031, according to projections by the Arthritis Foundation. This is likely to augment the global joint pain injections market in the next few years.
Growth in Sale of Hyaluronic Acid Injections to Create Lucrative Opportunities for Manufacturers
In terms of injection type, the global joint pain injections market has been divided into corticosteroid injections, hyaluronic acid injections, and others. The hyaluronic acid injections segment is projected to account for significant share of the global market during the forecast period. Large patient pool, preference for injections over surgeries, and approval of knee injections for the treatment of knee osteoarthritis are some of the factors that contribute to the increase in sale of hyaluronic acid injections. Furthermore, hyaluronic acid injections are quite effective in the treatment of knee osteoarthritis, while other treatments are contraindicated. This is likely to create lucrative opportunities for manufacturers to gain revenue benefits.
Increase in Prevalence of Knee & Ankle Injuries and Knee-related Disorders Bolstering Demand for Joint Pain Injections
Based on joint type, the knee & ankle segment accounted for major share of the global market in 2021. The segment is expected to grow at a high CAGR during the forecast period. Rise in prevalence of knee & ankle injuries and increase in incidence of knee-related disorders such as osteoarthritis and rheumatoid arthritis across the globe are contributing to the segment's large market share. The prevalence of knee osteoarthritis has doubled in the U.S. since the mid-20th century, largely due to the increase in life expectancy.
Rise in Preference for Viscosupplementation Augmenting Hospital Pharmacies Segment
In terms of distribution channel, the global joint pain injections market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospitals pharmacies segment is projected to account for major share of the global market in 2021. This can be ascribed to the rise in number of hospital admissions due to the increase in preference for new treatment options such as viscosupplementation.
Regional Outlook of Global Joint Pain Injections Market
North America is projected to account for major share of the global joint pain injections market during the forecast period. This can be ascribed to the high acceptance of viscosupplementation with hyaluronic acid products along with significant number of people in the region being covered by medical insurance. Furthermore, viscosupplementation has been approved by the U.S. FDA for the treatment of knee osteoarthritis. The U.S. dominated the joint pain injections market in North America in 2021 due to the presence of a large patient pool, high acceptance of newer orthobiologic injections such as platelet-rich plasma, and increase in geriatric population in the country.
Europe was the second largest region of the global joint pain injections market in terms of share in 2021. This can be ascribed to the rise in prevalence of joint pain among the population, increase in incidence of osteoarthritis, high acceptance of new treatments, surge in geriatric population, and approval of innovative products by the European Union. Germany led the joint pain market in the region in 2021 owing to its large patient population. The usage of hyaluronic acid is expected to rise significantly in Germany due to the increase in demand for effective treatments for osteoarthritis.
The market in Asia Pacific is anticipated to grow at a high CAGR during the forecast period due to the presence of a large patient pool, increase in treatment penetration, surge in geriatric population, and rise in awareness about joint-related disorders in India and China.
Analysis of Key Players in Global Joint Pain Injections Market
The global joint pain injections market is highly fragmented, with a small number of large-scale vendors controlling majority of the share. Most companies are investing significantly in comprehensive research and development activities, primarily to create innovative products. Expansion of product portfolios and mergers & acquisitions are the prominent strategies adopted by key players. The global joint pain injections market report includes various sections such as joint pain injections market drivers, joint pain injections market analysis, and challenges and opportunities in the joint pain injections market. Allergan plc, Pfizer, Inc., Sanofi, Anika Therapeutics, Inc., Ferring B.V., Bioventus, Flexion Therapeutics, Inc., Zimmer Biomet Holdings, Inc., Seikagaku Corporation, and Chugai Pharmaceutical Co., Ltd. are the key players operating in the global join pain injections market.
Key Developments in Global Joint Pain Injections Market
Some of the prominent players in the Joint Pain Injections Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Joint Pain Injections market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders